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Abstract 
Significance
Generalised selenoprotein deficiency has been associated with mutations in SECISBP2, 
SEPSECS and TRU-TCA1-1, three factors crucial for incorporation of the amino acid 
selenocysteine (Sec) into at least 25 human selenoproteins. SECISBP2 and TRU-TCA1-1 defects 
are characterised by a multisystem phenotype due to deficiencies of antioxidant and tissue-
specific selenoproteins, together with abnormal thyroid hormone levels reflecting impaired 
hormone metabolism by deiodinase selenoenzymes. SEPSECS mutations are associated with a 
predominantly neurological phenotype with progressive cerebello-cerebral atrophy.
Recent Advances
The recent identification of individuals with defects in genes encoding components of the 
selenocysteine insertion pathway has delineated complex and multisystem disorders, 
reflecting lack of selenoproteins in specific tissues, oxidative damage due to lack of 
oxidoreductase-active selenoproteins and other pathways whose nature is unclear. 
Critical Issues:
Abnormal thyroid hormone metabolism in patients can be corrected by T3 treatment. No 
specific therapies for other phenotypes (muscular dystrophy, male infertility, hearing loss, 
neurodegeneration) exist as yet, but their severity often requires supportive medical 
intervention. 
Future Directions.
These disorders provide unique insights into the role of selenoproteins in humans. The 
longterm consequences of reduced cellular antioxidant capacity remain unknown and future 
surveillance of patients may reveal time-dependent phenotypes (e.g. neoplasia, ageing) or 
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consequences of deficiency of selenoproteins whose function remains to be elucidated. The role 
of antioxidant therapies requires evaluation.
Page 3 of 47
Introduction
Selenium is an essential micronutrient which is incorporated as the amino acid selenocysteine 
(Sec) into human selenoproteins, encoded by 25 separate genes. Most selenoproteins function 
as oxidoreductases, with the Sec residue involved in catalytic activity. Selenoproteins have 
diverse functions ranging from maintenance of redox potential, regulating redox sensitive 
biochemical pathways, protection of genetic material, proteins and membranes from oxidative 
damage, metabolism of thyroid hormones, regulation of gene expression and control of protein 
folding (Table1). However, the function of several selenoproteins is unknown (57). 
Biosynthesis of selenoprotein requires an UGA codon within its mRNA to be recoded as the 
amino acid Sec, preventing its recognition as a premature stop, possibly targeting the transcript 
for nonsense mediated decay (NMD) (57, 79). This process is achieved via an unique Sec-
insertion machinery, comprising cis-acting SEleniumCysteine Insertion Sequence (SECIS) 
elements located in the 3’-UTR of selenoprotein mRNAs and the UGA codon, interacting with 
trans-acting factors (SECIS binding protein 2 (SECISBP2), Sec tRNA specific eukaryotic 
elongation factor (EEFSEC), Sec-tRNA[Ser]Sec) (Figure 1) (4, 24, 33, 58, 85).
In contrast to other amino acids, selenocysteine does not have an aminoacyl-tRNA synthetase, 
but is synthesised on its own tRNA, encoded by TRU-TCA1-1 (Figure 1) (5). This tRNA was 
originally named the human opal suppressor gene and a truncated pseudogene which is not 
expressed also exists (68). Delivery of   to the ribosome and subsequent cotranslational 
insertion of Sec is mediated by a multiprotein complex (81) which includes EEFSEC and 
SECISBP2 as well as other factors. The specialised elongation factor EEFSEC (rather than 
general elongation factors eEf1a and EF-Tu, which delivers all other aa-tRNAs, binds and 
delivers Sec-tRNA[Ser]Sec to the ribosome acceptor site (85). SECISBP2 interacts with the SECIS 
element, a stem–loop structure present in the 3’-UTR present of every selenoprotein mRNA 
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(12, 13, 23). SECIS elements within each selenoprotein mRNA are distinct, but share common 
structural features, consisting of two helices separated by an internal loop, a GA quartet of non-
Watson–Crick base pairs, and an apical loop, resulting in the adoption of a “kink-turn” structure 
(21, 33, 41, 89, 90). All selenoprotein mRNAs contain a single SECIS element, except for 
selenoprotein P (SELENOP) which has two, tandemly repeated SECIS elements. This 
configuration coincides with human SELENOP being the only selenoprotein which contains 
more than one selenocysteine residue (57). Whilst the SECIS element is required for Sec 
incorporation, other motifs in some selenoprotein mRNAs (e.g., Sec redefinition element, 
proximal stem loop element) have been described to contribute to the translation process
(15, 22, 47, 48, 62). 
The EEFSEC - Sec-tRNA[Ser]Sec - SECISBP2 complex, bound to SECIS in the selenoprotein mRNA, 
is thought to be in close proximity to the ribosomal complex, thereby preventing recognition of 
UGA as a translational stop and poised to mediate Sec incorporation into the polypeptide when 
the UGA codon is presented. Ribosomal protein L30 (RPL30), selenocysteine 1 associated 
protein 1 (TRNAU1AP), eukaryotic translation initiation factor 4A3 (EIF4A3) and nucleolin are 
other factors which regulate the Sec insertion process (Figure 1) (49, 57, 79).  However, three 
factors, Sec-tRNA[Ser]Sec, EEFSEC and SECISBP2, have been shown to be essential and sufficient 
for Sec incorporation in vitro (42, 59, 63, 82). 
The biological importance of selenoproteins is highlighted by the fact that Trsp (mouse 
tRNA[Ser]Sec) and Secisbp2 null mice are both embryonically lethal (19, 78). Mutations in 
individual human selenoproteins and their consequences have recently been reviewed in detail 
elsewhere (36): selenoprotein N (myopathy); glutathione peroxidase 4 (respiratory failure and 
skeletal defects); thioredoxin reductase 2 (associated with familial glucocorticoid deficiency 
and dilated cardiomyopathy); thioredoxin reductase 1 (generalized epilepsy); two reports 
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describe patients with a complex, hereditary spastic paraplegia and mutations in SELENOI, 
which catalyzes the transfer of phosphoethanolamine from CDP-ethanolamine to 
diacylglycerol to produce phosphatidylethanolamine (2, 46). Here, we describe mutations in 
genes (SEPSECS, SECISBP2 and TRU-TCA1-1) encoding three components of the selenocysteine 
insertion pathway, affecting general incorporation of selenocysteine into selenoproteins and 
their clinical consequences.
 SECISBP2 
SECISBP2 is an obligate limiting factor for selenoprotein synthesis, as first shown by absence 
of selenoprotein synthesis in SECISBP2-depleted cell lysates, with restoration of production by 
repletion with SECISBP2 (23, 24).  Human SECISBP2 is a large (854 amino acids, 120-kDa) 
protein, with the first 400, amino (N-) terminal, residues being dispensable for its function in 
vitro (25, 26) (Figure 2). In contrast, the C-terminal region (amino acids 399-784) is both 
necessary and sufficient for SECIS-binding and Sec incorporation in vitro and contains several 
functional domains. The Sec incorporation domain (SID), located centrally in SECISBP2, is not 
essential for SECIS binding but required for Sec incorporation. The RNA binding domain (RBD) 
contains an L7Ae-type RNA interaction motif identified in a large family of ribosomal proteins 
(e.g., RPL30, SUP1, eRF-1 and 15.5-kD/Snu13p) (4, 5, 16, 25, 26), which interacts with the 
“kink-turn” structure adopted by the SECIS-element. The RBD mediates interaction with the 
SECIS element (34, 90) and 28S ribosomal RNA (25, 49, 56, 59). A domain N-terminal to the 
L7Ae module, referred to as either the bipartite, SID or K-rich region, is involved in specific 
recognition of SECIS elements and other regulatory RNA motifs, thereby also controlling 
selenoprotein expression levels (17, 30, 83). SECISBP2 also contains several other functional 
motifs shown in Figure 2 (69). 
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Alternative splicing events in the 5’-region of human SECISBP2, with use of alternative initiation 
of translation from downstream ATG start codons in exons 2, 3a, 3b, 5 and 7, generates five 
different protein isoforms, each containing varying N-terminal protein sequence (Figure 2) (24, 
70). These alternate splicing events alter content of the dispensable N-terminal region, but not 
the essential C-terminal domain, within protein isoforms. Nevertheless, it is possible that the 
alternately spliced isoforms do play a role in regulation of SECISBP2-dependent Sec 
incorporation and selenoprotein expression in vivo. During protein synthesis dynamic 
interaction of SECISBP2 with the ribosome and SECIS element is essential for recruitment of 
the EEFsec/Sec-tRNA[Ser]sec complex to the UGA codon, enabling incorporation of Sec into the 
polypeptide. 
Homozygous or compound heterozygous mutations in SECISBP2 have been described in 13 
individuals from 11 families (Table 2).  Disruption of SECISBP2 function prevents appropriate 
Sec incorporation into selenoproteins during their biosynthesis resulting in a multisystem 
disorder due to deficiency of diverse selenoproteins (Table 3). The biochemical signature 
which identifies SECISBP2-deficient patients consists of low circulating selenium (reflecting 
low plasma SELENOP and GPX3) and abnormal thyroid hormone levels due to diminished 
activity of deiodinases (Table 3) (31, 75). Most cases present in childhood due to growth 
retardation with raised circulating FT4, normal to low FT3 and raised reverse T3 levels, 
reflecting deficiency of all three deiodinase enzymes. 
Muscle weakness, due to progressive rigid spine muscular dystrophy, affecting axial and 
proximal limb muscles with raised creatine kinase (CK) levels and fatty infiltration on imaging, 
is similar to that seen in patients with mutations in selenoprotein N. In one patient (proband 
E), male azoospermic infertility was described, reflecting loss of testis selenoproteins 
(mitochondrial GPX4, thioredoxin reductase, selenoprotein V) required for spermatogenesis 
(75). 
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Significantly decreased expression levels of antioxidant selenoenzymes are associated with 
increased levels of cellular reactive oxygen species (ROS). Clinical consequences of raised 
cellular ROS include skin photosensitivity, progressive sensorineural hearing loss and possibly 
increased total body adipose tissue mass paradoxically associated with enhanced systemic 
insulin sensitivity (75).  
Reduced red blood cell and total lymphocyte counts, with impaired mononuclear cell cytokine 
secretion and T-cell proliferation (similar to findings in T cell-specific Trsp null mice (80)), 
were recorded in one case, proband E (75). Although other haematological and immune cell 
phenotypes have not been formally evaluated, immunodeficiency is not a reported feature in 
other SECISBP2 mutation cases nor seen in mouse models of selenoprotein deficiency. 
Additional age-dependent phenotypes such as neurodegeneration, premature ageing or 
neoplasia may emerge but have not been described hitherto.  
Oral selenium supplementation in some SECISBP2 patients raised total serum Se levels, but 
without clinical effect (9, 20, 28) or altering synthesis (circulating GPX’s, SELENOP) or action 
(thyroid hormone metabolism) of selenoproteins (77). Treatment of probands C and F with T3 
alone (T4 was not effective in one case) or in combination with growth hormone (proband G) 
resulted in an improvement in growth, development and bone maturation. Treatment of 
proband G with a combination of alpha tocopherol (vitamin E) and T3 resulted in the most 
promising response, with decreased serum levels of lipid peroxidation products, altered FT4 
and FT3 concentrations and increased circulating white blood cells and neutrophils, all of 
which reversed after treatment withdrawal (74). These observations suggest that treatment 
with antioxidants, to counteract effects of elevated cellular ROS, are the best available 
therapeutic option for this disorder. 
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Most SECISBP2 mutations identified to date cause premature stop codons, resulting in absence 
of full length SECISBP2 protein. However, elegant minigene experiments have shown that, for 
premature stops located in the N-terminal part of the protein, initiation of translation from 
alternative, downstream ATG codons in exons 5 (Met233) and 7 (Met300), permits low-level 
synthesis of shorter SECISBP2 isoforms (28, 75).  Some premature stop mutations are situated 
downstream of Met300 and may completely eliminate synthesis of functional protein. 
However, stop mutations (e.g. R770X, Q782X), distal to the RBD might generate C-terminally 
truncated proteins whose RNA binding and nuclear localisation functions remain, partially, 
intact (Figure 2). In a patient with defective mRNA splicing due to an intronic mutation 
IVS8ds+29G>A (31) it has been shown that levels of normally spliced transcript are only 
reduced by 50% and if a similar mechanism operates with other splice site mutations, this 
suggests some preservation of normally spliced SECISBP2 mRNA in such cases.
Three missense SECISBP2 mutations (R540Q, C691R and E679D) have been described: The 
R540Q mutation localises to the K-rich region within the RBD (Figure 2), with the R540Q 
mutant exhibiting reduced binding to SECIS elements in GPX1 and DIO2 mRNAs, correlating 
with diminished GPX1 and DIO2 enzyme activity in patient-derived primary cells and mouse 
model. Detailed analyses suggests that R540Q mutant SECISBP2 fails to bind only a subset of 
SECIS-elements, consistent with the K-rich region mediating recognition of specific (type I and 
type II) SECIS elements (14) and a mouse model revealed a possible tissue specific pattern of 
SECISBP2 protein stability correlating with varying loss or preservation of expression of 
different selenoproteins (14, 31, 96).  
The C691R SECISBP2 mutation, also located in its RBD, is expected to affect RNA binding. 
Homology modelling, based on the crystal structure of the spliceosomal 15.5 kDa protein (87), 
suggests that mutation of cysteine to a bulky and charged arginine residue (75) may destabilise 
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its hydrophobic core, disrupting local protein structure (Figure 2 B and C). In vitro assays, 
showing enhanced proteasomal degradation of the C691R mutant SECISBP2 protein, 
confirmed this (75). A mouse model suggests that the C691R mutant SECISBP2 is unable to 
bind RNA and non-functional (96). The E679D SECISBP2 mutation is predicted to be 
deleterious (PolyPhen-2 algorithm score of 0.998 and also located in the RBD and may 
therefore affect its RNA binding function, but this has not been investigated in detail (37) 
(Figure 2). 
Knowledge that knockout of Secisbp2 in mice is embryonic lethal (78), with no evidence for an 
alternative Sec-incorporation mechanism in humans, suggests that there is some residual 
SECISBP2 activity in all patients. All patients described to date are expected to harbour at least 
one allele which directs synthesis of SECISBP2 at either reduced levels or which is only partially 
functional, in combination with either a mutant or shorter form of the protein synthesised from 
Met300 (Table 2).  A limited number of patients, mostly compound heterozygous for different 
SECISBP2 mutation combinations, with limited knowledge of phenotypes in heterozygous 
relatives, have been described, making it difficult to assess the effect of a specific SECISBP2 
mutation or its correlation with severity of phenotype. However, since SECISBP2 is rate limiting 
for Sec incorporation, a significant reduction in functional SECISBP2 protein levels will result 
in diminished but not complete loss of selenoprotein synthesis. A further variable is that 
differences in architecture of SECIS elements within different selenoprotein mRNAs may 
dictate the extent to which reduced SECISBP2 protein limits their biosynthesis and expression 
levels in vivo, as suggested by elegant experiments testing SECISBP2 with luciferase reporter 
genes containing different SECIS elements (60, 84). Future studies, undertaking ribosomal RNA 
(96) or selenoprotein expression profiling in secisbp2 mutant mouse models and in vitro 
reconstitution experiments with different mutant SECISBP2 proteins and SECIS element 
containing luciferase reporter genes (84), may help us better understand the effect of specific 
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SECISBP2 mutations. In turn, greater understanding of how different mutations affect 
selenoprotein expression, may enable better prediction of clinical outcome or targeting of 
therapy in patients. 
TRU-TCA1-1
Selenocysteine is synthesised on its own tRNA (Figure 1), tRNA[Ser]Sec (encoded by TRU-TCA1-
1) which has several unique features, being longer (90 nucleotides versus usual 78), with an 
atypical long acceptor- and D-stem with few modified bases (57) that distinguishes it from 
other tRNAs (Figure 3A). Its promoter region, containing both tRNA and U snRNA gene 
regulatory elements (18, 39, 44) forming a new class of RNA polymerase III transcribed genes, 
also differs from other tRNA genes (Figure 3B) and consists of four regulatory elements: an 
activator element, containing an SPH motif, but is octamer independent; the proximal sequence 
element; an extended TATA-motif, essential for efficient transcription and an internal B box (64, 65).
Two major isoforms of Sec-tRNA[Ser]Sec have been identified, containing either 5-
methoxycarbonyl-methyluridine (mcm5U) or its methylated form 5-methoxycarbonylmethyl-
2’-O-methyluridine (mcm5Um) at position 34 (Figure 3C). Uridine 34 is located in the anticodon 
loop and its methylation may contribute to stabilization of the codon-anticodon interaction (19, 
27, 45, 79). Methylation at uridine 34 is executed by a methylase whose identity is not known 
and the relative abundance of the two Sec-tRNA[Ser]Sec isoforms is known to be influenced by 
systemic Se-status, increasing selenium levels resulting in more mcm5Um isoform (19, 27, 45). 
Each Sec-tRNA[Ser]Sec subtype has a different role, with synthesis of cellular housekeeping 
selenoproteins (e.g., TXNRD1, TXNRD3, GPX4) being dependent on the mcm5U isoform, 
whereas expression of cellular, stress-related selenoproteins (e.g., GPX1, GPX3, SELENOW), 
requires the mcm5Um isoform (19, 79). Methylation of mcm5U, the final step in 
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posttranscriptional maturation of Sec-tRNA[Ser]Sec, is dependent on correct aminoacylation (53, 
54), intact secondary/tertiary structure (53) and other, prior, base modifications (Figure 3A) 
of the transfer RNA (27). 
A single patient, homozygous for a single nucleotide change (C65G) in TRU-TCA1-1 has been 
identified (Figure 3A) (76). The proband exhibits a similar phenotype to that seen in SECISBP2 
mutation patients. However, comparison of cellular selenoprotein expression profiles in the 
two disorders has revealed differences, with expression of relative housekeeping 
selenoproteins (e.g., TXNRDs, GPX4) being more preserved than in SECISBP2 cases. In contrast, 
expression of stress-related selenoproteins (e.g., GPX1, GPX3) was similarly reduced in both 
disorders. In primary cells from the TRU-TCA1-1 mutation patient, lower total tRNA[Ser]Sec 
expression with disproportionately greater diminution in Sec-tRNA[Ser]Sec mcm5Um levels was 
observed, with decreased i6A modification at position 37 suggesting that its posttranscriptional 
maturation is impaired. The mutation had no effect on tRNA[Ser]Sec aminoacylation with serine 
or Sec synthesis or its interaction with SEPSECS. Low levels of tRNA[Ser]Sec in the proband were 
insufficient to direct normal synthesis of stress-related selenoproteins, but were not rate 
limiting for adequate synthesis of some housekeeping selenoproteins and similar, differential 
preservation of selenoprotein synthesis has been observed in murine tRNAsec mutant models 
(19, 57). 
The human SEPSECS - tRNA[Ser]Sec structure shows that C65 is situated in the acceptor arm, next 
to C64 in TΨC–arm (Figure 3D). C64 interacts with Lys38 and Glu37 in helix 1 of the non-
catalytic part of the SEPSECS moiety (Figure 3E), raising the possibility that the C65G mutation 
could affect the stability of the Sec-tRNA[Ser]Sec - SEPSECS complex and the selenoprotein 
synthesis. 
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In summary, these observations indicate that reduction in Sec-tRNA[Ser]Sec levels, with 
particular deficiency of the Sec-tRNA[Ser]Sec mcm5Um subtype, contributes to the selective 
pattern of selenoprotein deficiency seen in the proband. The precise mechanism mediating 
reduction in mutant Sec-tRNA[Ser]Sec presence remains unclear, with  defective 
posttranscriptional modification of  mutant Sec-tRNA[Ser]Sec or instability of the mutant Sec-
tRNA[Ser]Sec -SEPSECS complex being possibilities.  
SEPSECS 
Human SEPSECS was initially identified as an autoantigen (soluble liver antigen/liver pancreas, 
SLA/LP) in autoimmune hepatitis (52). Subsequent studies in which mammalian cell extracts 
were treated with autoimmune hepatitis patients’ serum, showed that SEPSECS co-precipitated 
with Sec-tRNA[Ser]Sec, as part of a ribonucleoprotein complex (40). This led to the identification 
of SEPSECS as the enzyme which catalyses conversion of O-phosphoserine-tRNA[Ser]Sec to Sec-
tRNA[Ser]Sec, using selenophosphate as donor substrate (81, 93) (Figure 1). 
Crystal structures of the archaeal and murine Sepsecs apo-enzymes as well as human wild type 
and mutant SEPSECS complexed with Sec-tRNA[Ser]Sec have been solved, suggesting  that 
SEPSECS is a distinct member of the fold type I family of pyridoxal phosphate-dependent 
enzyme family (7, 38, 71, 73). The human structure shows a complex containing a SEPSECS 
tetramer binding two Sec-tRNA[Ser]Sec molecules through their long acceptor-TΨC arms, with 
the non-catalytic SEPSECS dimer mediating RNA-protein interactions which stabilize the 
complex and the CCA end of Ser-tRNA[Ser]Sec residing in the active site of the catalytic SEPSECS 
dimer (Figure 3D, 4B). The conversion of Ser-tRNA[Ser]Sec to Sec-tRNA[Ser]Sec by SEPSECS is 
pyridoxal-5-phosphate (PLP) cofactor dependent, with the proposed mechanism involving a 
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conformational change in SEPSECS upon Ser-tRNA[Ser]Sec binding, enabling the phosphoserine 
of Ser-tRNA[Ser]Sec to be oriented correctly for conversion to occur (71).
Homozygous and compound heterozygous mutations in SEPSECS (Table 4, Figure 4, 5) are 
associated with profound intellectual disability, global developmental delay, spasticity, 
epilepsy and hypotonia with progressive microcephaly due to cortical and cerebellar atrophy 
on magnetic resonance imaging (1). Additional phenotypes described in other patients include 
axonal neuropathy, optic atrophy and early onset epileptic encephalopathy with burst 
suppression (6, 67, 72). The timing of presentation in patients with SEPSECS mutations is 
variable, ranging from severe prenatal onset to delayed postnatal presentation and a mild, late 
onset phenotype in three patients (50, 86). This disorder is classified as autosomal recessive 
pontocerebellar hypoplasia type 2D (PCH2D, OMIM # 613811), also known as progressive 
cerebellocerebral atrophy (PCCA) (1, 11). Mice, homozygous for a SEPSECS mutation (Y334C) 
present with Sedaghatian
-type spondylometaphyseal dysplasia and die shortly after birth, in contrast to humans with 
the same mutation. This divergence in phenotype may be due to species differences, dietary 
environment or the genetic background of the mouse line used (35).  
The effect of SEPSECS mutations on selenoprotein expression has only been studied in 4 
patients (Family E, G, F; 6). In brain tissue levels of TXNRD1, TXNRD2, GPX1 and GPX4 proteins 
are reduced, correlating with increased cellular oxidative stress. However, selenoprotein 
deficiency is not generalised with normal TXNRD levels in patient’s fibroblast and muscle cells 
suggesting that residual SEPSECS activity preserves selenoprotein synthesis in some tissues or 
existence of alternative pathway(s). Consistent with findings in human tissues Sepsecs mutant 
mice exhibit decreased Gpx4 expression in neurons but not hepatocytes (35).
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Although the selenium content of brain is not high (95) it is kept very stable (10, 66) 
exemplified by the fact that in systemic selenium deficiency circulating selenoprotein P delivers 
this trace element preferentially to this organ at the expense of other tissues (66). This may 
explain why a reduction in SEPSECS activity could have a greater effect on brain development 
and function compared to other tissues. 
It is remarkable that an overt central nervous system phenotype is not reported in patients 
with SECISBP2 and TRU-TCA1-1 defects, but with most individuals with these mutations being 
children the possibility of a late onset neurological phenotype cannot be discounted. However, 
a neurodegenerative phenotype has been described in brain-specific Gpx4, Trsp and Secisbp2 
KO mouse models suggesting that Se deficiency and/or reduced redox capacity has a larger 
impact on the mouse brain compared to the human (78, 91, 92). 
Biochemical hallmarks of selenoprotein deficiency in SECISBP2 and TRU-TCA1-1 mutation 
cases include low circulating selenium and abnormal thyroid hormone levels, reflecting 
deficiency of circulating selenoproteins (SEPP, GPx3) or all three deiodinase enzymes 
respectively (31, 75). In SEPSECS mutation patients low serum selenium is not reported to be 
part of the phenotype and thyroid status has only been partially investigated in four patients, 
documenting either normal thyroid hormone (Family H; 72) or normal T4 but elevated TSH 
levels (Family E, G, F; 6). However more detailed investigation, with measurement of T3 or 
reverse T3 levels, which would be abnormal with decreased deiodinase enzyme activity, has 
not been undertaken in SEPSECS mutation cases (6). Myopathic features with raised CK levels, 
abnormal mitochondria, cytoplasmic bodies and increased lipid accumulation in muscle have 
been documented in one SEPSECS  mutation case (Family H; 72), with broad-based gait and 
postural instability suggesting muscle weakness in another patient (Family O, 86). Similar 
findings have been noted in adult SECISBP2 mutation patients, reflecting deficiency of 
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selenoprotein N and altered redox capacity in skeletal muscle (75). Overall, these observations 
suggests that some SEPSECS mutation patients can exhibit phenotypes associated with more 
global deficiency of selenoproteins. It is also possible that severity of neurological problems in 
patients has precluded detailed investigation and ascertainment of non-neurological 
phenotypes. 
The availability of the crystal structure of human SEPSECS - tRNA[Ser]Sec (71, 73) (Figure 4 and 
5) together with an SEPSECS activity assay using an E. coli strain lacking endogenous Sec-
synthase (SelA) activity (94), has enabled detailed studies of some SEPSECS (A239T, Y334C, 
T325S and Y429X) mutations (1, 6, 73). These pathogenic variants were found to be less soluble 
than WT protein in vitro, with loss of functional activity. A239T mutant SEPSECS failed to form 
stable tetramers, possible as result of a steric clash destabilizing two helices (H8-H9) within 
the enzyme’s core.  Y334C and T325S SEPSECS mutants are predicted to fold like wild type 
SEPSECS in the crystal structure and retain binding  to tRNA[Ser]Sec (73) but affect its catalytic 
pocket, reducing enzyme activity (1, 6, 73). Mutation of Tyr334 to Histidine is also recorded (6) 
and in silico analysis predicts that this variant is likely to have a similar deleterious effect as the 
Y334C mutation (Figure 5). The premature stop SEPSECS mutant (Y429X) is insoluble and 
inactive (6, 73) and three other premature stop mutants (Table 4) can be expected to have a 
similar effect. 
In silico analysis predicts that the A59V SEPSECS mutation results in steric hindrance 
destabilising helix 2 and helix 3, possible affecting its catalytic function and/or dimerization 
(Figure 5). The N119S SEPSECS mutation is a conservative amino acid substitution with a 
probable small effect, weakening an H-bond network in the non-catalytic dimer possibly 
affecting RNA interaction. Likewise, mutation of Arg156 to Glutamine in SEPSECS is a 
conservative change, predicted to perturb local structure minimally and possibly reducing 
activity of the catalytic site (Figure 5). The G441R SEPSECS mutation, situated close to the 
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catalytic site, changes the side chain of this amino acid from small and neutral to large and 
polar, but as Gly441 is situated within a loop, its possible effect on catalytic activity might be 
limited. Absence of two SEPSECS mutations (M1V, D489V) from crystal structures precludes in 
silico analyses: M1V affects the first methionine in SEPSECS and unless an alternative start 
codon (e.g., position 61) is used, no protein will be generated; the D489V mutation changes the 
size and charge of this amino acid and can therefore be expected to have a major impact on 
protein function/stability.
Three SEPSECS mutation patients (patient I (R26Pfs*42 - N119S); J (N119S - R156Q); O 
(G441R) presented with late onset PCH2D, with progressive but milder degree of CNS atrophy 
(50, 86). In silico analyses suggest that these mutations have a less deleterious effect on 
SEPSECS function (Figure 5), but it is also conceivable that environmental factors or patients’ 
genetic background may have modulated their phenotype. Future studies need to investigate 
the relationship between mutations, their effect on SEPSECS protein function and general 
expression of selenoproteins in different tissues and patient phenotypes in more detail.
Conclusions
SECISBP2, Sec-tRNA[Ser]Sec and SEPSECS are essential components of the selenoprotein 
biosynthesis pathway. Unsurprisingly, in patients, harbouring mutations in any of these genes, 
expression of most members of the selenoproteome is affected, sometimes in a tissue specific 
manner, resulting in a complex, multisystem phenotype. The combination of the nature of the 
gene defect, genetic/ethnic background of individuals and environmental factors (e.g., 
selenium and/or iodine status), might also contribute to inter-individual differences in 
phenotypes. Further complexity is due to the fact that most patients harbour compound 
heterozygous mutations with monoallelic mutations in individuals having no reported 
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phenotype. This makes it difficult to assess the effect of a particular mutation on the Sec-
incorporation pathway. Although a substantial body of knowledge regarding the individual 
functions of SECISBP2, Sec-tRNA[Ser]Sec and SEPSECS exists we do not have a comprehensive 
understanding of the Sec-insertion pathway. Nevertheless most observations in patients with 
gene defects accord with our current knowledge of this pathway. However, it is interesting that 
mutations in SECISBP2 and TRU-TCA1-1 present with similar phenotypes (growth retardation 
and myopathy together with abnormal thyroid function), whereas the dominant phenotype in 
SEPSECS mutation cases is progressive cerebellocerebral atrophy. 
In all patients some phenotypes (e.g., photosensitivity, age-dependent hearing loss, 
neurodegeneration) are clearly progressive, perhaps reflecting absence of antioxidant 
selenoenzymes resulting in cumulative oxidative damage to DNA, proteins and membrane 
lipids and dysfunction of redox-dependent signalling pathways. Some phenotypes can clearly 
be linked to deficiency of specific selenoproteins (e.g., abnormal thyroid function and DIO1,2,3; 
low plasma Se and SELENOP, GPX3; azoospermia and SELENOV, GPX4, TXRND3; myopathy and 
SELENON). 
However, the precise role of many selenoproteins in human biological processes is unknown, 
making identification of causal links between altered expression of specific selenoproteins and 
human disease a particular challenge. Furthermore, the role of individual selenoproteins needs 
to be analysed in the context of a complex cellular biochemical environment, where 
antagonistic, additive and synergistic effects can occur. Recent advances including analysing 
selenoprotein expression in mouse models, RNA ribosome profiling (96) in vitro technologies 
like  CRISPR-Cas9-VLP (88), dissection of SECIS and other functional RNA elements (22, 62) 
using luciferase-based reporter  assays (84), modelling using crystal structures (e.g., SEPSECS 
- Sec-tRNA[Ser]Sec , EEFSEC ) (29), can help us better understand the complex Sec-insertion 
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pathway in general and more specifically the effect of mutations in genes within this pathway 
and their consequences on selenoprotein expression. This knowledge will provide the essential 
basis for understanding the pathogenesis of human disease due to generalised or specific 
selenoprotein deficiencies and may enable identification of therapies targeted at specific 
processes (e.g. oxidative stress) in which selenoproteins play a key role.
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Figure legends Erik Schoenmakers
Figure 1 Pathway of selenocysteine synthesis and its incorporation into selenoproteins.
Sec is synthesised on its own tRNA (tRNA[Ser]Sec), which undergoes maturation through 
sequential modifications, with initial attachment of serine by seryl-tRNA synthetase 
(SARS) resulting in Ser-tRNA[Ser]Sec. Subsequent phosphorylation of this serine residue by 
phosphoseryl-tRNA kinase (PSTK) generates O-Phosphoseryl-tRNA[Ser]Sec. Finally, O-
phosphoserine tRNA:Sec tRNA synthase (SEPSECS) catalyses the acceptance of a 
selenophosphate, generated from selenide and ATP by selenophosphate synthetase 2 
(SEPHS2), resulting in Sec-tRNA[Ser]Sec. An intermediate complex which includes Sec-
tRNA[Ser]Sec, tRNA selenocysteine 1 associated protein 1 (TRNAU1AP) and EEFSEC, is 
formed subsequently. This complex is guided by interaction with SECISBP2 to the SECIS-
element of selenoprotein mRNA, ready for incorporation into the nascent polypeptide. 
Other factors (ribosomal protein L30, eukaryotic initiation factor eIF4a3, nucleolin, …) 
also have regulatory roles and influence the Sec insertion process.  To see this illustration 
in color, the reader is referred to the online version of this article at 
www.liebertpub.com/ars.
Figure 2. A. The organisation of the SECISBP2 gene (top), with naturally-occuring 
aminoterminal splice variants, each containing distal exons 8 to 17 shown below; the 
functional domains of SECISBP2 protein with the location of human mutations 
superimposed is shown (bottom). Arrowheads denote the location of ATG codons, which 
could function as alternative sites for initiation of translation. Functional domains in 
SECISBP2 protein: N-terminal domain (1-399); minimal functional protein (shaded grey, 
399-784); Sec incorporation domain (SID, 399-517); minimal RNA-binding domain (RBD, 
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517-784); Lysine-rich domain involved in RNA specificity and ribosome binding (517-
544); L7Ae homology module (620-745); nuclear localisation signal (NLS, 380-390); 
redox-sensitive cysteine-rich domain (CRD, 584-854) and two nuclear export signals 
(NES1: 634-657; NES2: 756-770) (69).
B. and C. Model of the L7ae RNA-binding domain of SECISBP2. The position of wild type 
residues (E679, C691) (panel B) and corresponding mutations (E679D, C691R) at these 
locations (panel C) is shown. The model was generated using the phyre2 (Protein 
Homology/analogy Recognition Engine 2) web portal, which predicts and analyses 
protein structures based on homology/analogy to solved protein crystal structures (51) 
The figures were generated with MacPyMOL Molecular Graphics System, Schrödinger, 
LLC.
Figure 3 A. The primary structure of human Sec-tRNA[Ser]Sec is shown in a cloverleaf 
model, with the location of C65G TRU-TCA1-1 mutation identified in the patient indicated 
(circled red). The acceptor stem constitutes paired 5’ and 3’ terminal bases, with the D 
arm, the anticodon arm, the variable arm and the TψC arm depicted. Mammalian Sec-
tRNA[Ser]Sec undergoes posttranscriptional modification at positions 34 (mcm5U or 
mcm5Um), 37 (i6A), 55 (ψ) and 58 (m1A). B. Schematic of the TRU-TCA1-1 gene showing 
the coding region (black box) and regulatory elements (grey boxes) (43) with the location 
of C65G mutation identified in the patient. C. The two Sec-tRNA[Ser]Sec isoforms, containing 
either mcm5U or mcm5Um modifications of the uracil at position 34 in the anticodon 
arm, differ from each other by a single methyl group on the 2’-O-ribosyl moiety. This 
reaction is catalysed by an unknown methylase and abundance of the mcm5Um isoform 
increases with selenium concentration (19). D. Crystal structure showing catalytic and 
non-catalytic dimers of the SEPSECS tetramer bound to tRNA[Ser]Sec (71), with the position 
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of the C65 nucleotide indicated. Other nucleotides in tRNA[Ser]Sec (cyan) and amino acids 
in SEPSECS (yellow) involved in RNA-protein interaction are also highlighted, as are the 
nucleotides (red) towards  the position of Sec and the pyridoxal-5-phosphate substrate 
(green) within the catalytic domain. E. A close-up of the structure around C65, showing 
H-bonds (dashed green lines) formed between C64 and the C64-C65 backbone with 
residues (E37 and K38) situated in helix 1 (H1) of the non-catalytic dimer of SEPSECS. To 
see this illustration in color, the reader is referred to the online version of this article at 
www.liebertpub.com/ars.
Figure 4. A. The organisation of human SEPSECS gene (top) and schematic of SEPSECS 
protein (bottom) with the location of human mutations superimposed. Arrowhead 
denotes the location of the ATG start codon. B.  Crystal structure showing a single 
catalytic – non-catalytic dimer from the complex bound to tRNA[Ser]Sec, with the position 
of all the human SEPSECS point mutations superimposed (71). Mutations associated with 
early onset (red) or late–onset (yellow) disease and the pyridoxal-5-phosphate (cyan) 
substrate are highlighted. To see this illustration in color, the reader is referred to the 
online version of this article at www.liebertpub.com/ars.
Figure 5. Detailed views comparing wild type SEPSECS crystal structure and mutated 
amino acids modelled in the SEPSECS crystal structure which cause either early-onset 
(red) or late onset (yellow) disease (71). Hydrogen bonds (dotted green lines), pyridoxal-
5-phosphate substrate (cyan), tRNA (orange) and H2O (blue) are shown. The helices (H), 
beta-sheets (β), amino acids and nucleotides involved in hydrogen bond networks or 
which are part of the active catalytic domain are labelled. Crystal structures for T325S 
and Y334C SEPSECS mutants are available and in the panels with these mutations an 
overlay of wild type (grey) and mutant (cyan) is shown (73). For more detailed 
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information see text. The model was generated using the phyre2 web portal, which 
predicts and analyses protein structures based on homology/analogy recognition to 
solved protein crystal structures (51). The figures were generated with MacPyMOL 
Molecular Graphics System, Schrödinger, LLC.  To see this illustration in color, the reader 
is referred to the online version of this article at www.liebertpub.com/ars.
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Table 1 Selenoproteins
Selenoprotein main known function Subcellular Localization expression pattern
GPX1 Oxidoreductase cytoplasmic most tissues
protection against oxidative stress
GPX2 Oxidoreductase                          
protection against oxidative stress
Nuclear and cytoplasmic Gastrointestinal tract, bone marrow,immune 
system,liver,galbladder,kidney, urinary bladder
GPX3 Oxidoreductase                          
protection against oxidative stress
secreted most tissues , high in kidney, thyroid, adipose
GPX4 Oxidoreductase Nucleus and mitochondria most tissues, high in testis, adipose tissue
protection against oxidative stress
GPX6 Oxidoreductase predicted secreted testis, epididymis, olfactory system
protection against oxidative stress
TXNRD1 Oxidoreductase Nuclear and cytoplasmic Ubiquitous 
protection against oxidative stress
TXNRD2 Oxidoreductase cytoplasmic and mitochondria Ubiquitous 
protection against oxidative stress
TXNRD3 Oxidoreductase Intracellular most tissues, high in testis
protection against oxidative stress




kidney, liver, thyroid gland




low in several tissues, high in thyroid, esophagus,
cervix,ectocervix,pituitary,endometrium,brain




 several tissues, high in cervix, uterine, placenta, 
urinary bladder
MSRB1 Oxidoreductase Nuclear and cytoplasmic Ubiquitous 
Methionine Sulfoxide Reduction
SELENOF Oxidoreductase  endoplasmic reticulum Ubiquitous 
ER-associated protein folding control
SELENOH unknown Oxidoreductase nuclear Ubiquitous 
dna/rna binding motif
SELENOI Oxidoreductase transmembrane Ubiquitous 
phospholipid biosynthesis
SELENOK ER-associated protein folding control ER, plasma membrane Ubiquitous 
SELENOM unknown Nuclear and perinuclear Ubiquitous 
SELENON Oxidoreductase  endoplasmic reticulum Ubiquitous 
redox-related calcium homeostasis
SELENOO Protein AMPylation activity  mitochondria Ubiquitous 
SELENOP transport / Oxidoreductase secreted, cytoplasmic most tissues, high in liver and small intestine
SELENOS Oxidoreductase  endoplasmic reticulum Ubiquitous 
ER-associated protein folding control
SELENOT unknown Oxidoreductase  endoplasmic reticulum Ubiquitous 
SELENOV unknown Intracellular thyroid, parathyroid, testis, brain
SELENOW Oxidoreductase Intracellular Ubiquitous 
protection against oxidative stress
SEPHS2 selenophosphate synthesis Intracellular Ubiquitous, high in liver kidney
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Table 2 Human SECISBP2 mutations: genetics and effect
Family Gene Mutation Predicted protein change
Alleles 
Affected Suggested Mechanism Ethnicity Ref






premature stop, no/decreased full 
length protein    
Irish/
Kenyan 31
C c.382 C>T R128X homozygous premature stop, no full-length protein Ghanaian 28
c.358 C>T R120X premature stop, no full-length proteinD
c.2308 C>T R770X
compound 
heterozygous premature stop, no full-length protein
Brazilian 9
c.668delT F223fs255X premature stop, no full-length protein
E
c.IVS7 -155, T>A fs295X+fs302X
compound 
heterozygous premature stop, no or decreased full 
length protein
British 75
c. 2017T>C C691R compound predicted to affect SECIS & ribosome binding, increased degradationF











heterozygous premature stop, no full-length protein Turkish 32
c.660 C>T R197X premature stop, no full-length protein /splice variants affectedI
c.2108 G>  T or C E679D
compound 
heterozygous predicted to affect SECIS & ribosome 
binding
Argentinian 37




heterozygous premature stop, no full-length protein N/A 55
N/A not available
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Table 3 Human SECISBP2 mutations: A multisystem disorder with a thyroid signature
Family [Se] TT4 FT4 TT3 rT3 TSH Growth & Skeletal Musculoskeletal Neurocognitive Hearing other
A L H H L H H Short stature, DBA N/A Normal mental development normal N/A
B L H H N/L H N Short stature, DBA N/A N/A normal N/A
C L H H N/L H N Short stature, DBA N/A N/A N/A




hypotonia, hip girdle weakness, 
Spirometry: reduced expiratory & 
inspiratory flow, fatty infiltration of muscle





Failure to thrive, Bilateral clinodactyly, 
Asymmetric leg length, Peripheral sensory 
neuropathy, Increased fat mass
E L N/A H N N/A N short stature, Genu valgus
Lumbar spinal rigidity, reduced axial & 
neck strength, Spirometry: reduced vital 






Azoopsermia, Raynauds disease, 
Photosensitivity, mild lymphopenia and 
reduced red cell mass,  Low insulin and 
high adiponectin levels, favourable blood 
lipid profile, low intrahepatic lipid
 F L N/A H L N/A N Short Stature
Proximal & axial myopathy, lumbar 






Failure to thrive, eosinophilic colitis, 
Increased fat mass, high adiponectin levels, 
hypoglycaemia with low fasting insulin
G L N/A H N/L N/A N/H Short Stature, DBA Fatty infiltration of muscles





Failure to thrive, hypoplastic thyroid gland, 
no photosensitivity, increased fat mass
H L H H L H N/H Short Stature N/A Mental and motor retardation, IQ 50 N/A N/A
I N/A H H L H N DBA N/A N/A N/A Failure to thrive




muscle weakness, fatty infiltration of the 
muscles Normal early development normal
Right-eye ptosis, attention-deficit disorder 
with poor school performance, impaired 
growth hormone response, obese (BMI 
29.5), impaired OGTT
K N/A H H L H N Short Stature, DBA N/A Developmental delay N/A Failure to thrive
L L H H L H N delayed growth
hypotonia, myopathy with fatty infiltration 




dysarthic speech, tapered fingers, seizures, 
Increased fat mass
DBA, delayed bone age; Se, selenium; T3, triiodothyronine; T4, thyroxine; TT4 total T4; FT4 free T4; TT3 total T3; rT3 reverse T3; TSH thyroid stimulating; 
hormone; L, low; H high; N normal; N/L low normal; N/H, high-normal; N/A not available; IQ, intelligence quotient; OGTT oral glucose tolerance test
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Affected Suggested Mechanism Ethnicity Phenotype Ref
















premature stop, no full length protein
Finnish PCH2D 6
H c.1001A>C Y334H homozygous predicted to affect folding and reduce catalytic activity Arabian PCH2D 72




heterozygous predicted reduced catalytic 
activity/RNA binding
Japanese late onset PCH2D 50




predicted reduced catalytic activity
Japanese late onset PCH2D 50




premature stop, no full length protein
N/A PCH2D 97





M c.1027-1120del E343Lfs*2 homozygous premature stop, no full length protein N/A
Neurodegenerative 
disease 3
N c.176C>T A59V homozygous predicted to affect folding, dimerisation and reduce activity N/A EOEE-BS; PCH2D 67
O c. 1321G>A G441R homozygous predicted to reduce catalytic activity N/A late onset PCH2D 86
P N/A N/A N/A N/A N/A  PCH2D 8
EOEE-BS: early onset epileptic encephalopathy with burst suppression; PCH2D: pontocerebellar 
hypoplasia type 2D; N/A not available
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